INFORMAZIONI SU QUESTO ARTICOLO
Pubblicato online: 30 giu 2018
Pagine: 98 - 103
Ricevuto: 16 gen 2018
Accettato: 27 feb 2018
DOI: https://doi.org/10.1515/jbcr-2017-0016
Parole chiave
© 2017 Savelina L. Popovska et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Lung cancer is still the leading cancer-related cause of death with a high incidence rate in the whole world. Treatment options – surgery, radiotherapy, and chemotherapy, depending on the stage of the disease. During the last decade, many molecular alterations were discovered that led to impressive changes in treatment. Personalized approaches, including target therapies with specific inhibitor drugs, became a part of the standard therapies. This article reviews current molecular biomarkers used in clinical practice to treat lung cancer patients.